Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2007-07-28 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
2007年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a '2007 年半年度报告' which translates to '2007 Half-Year Report' or 'Interim Report'. It contains detailed financial data for the first half of 2007, including balance sheet items, profit and loss figures, shareholder information, management changes, and operational commentary. The report is comprehensive and includes unaudited financial statements, management discussion, and other disclosures typical of an interim or quarterly report. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is the actual report, not just an announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2007
2007-07-28 Chinese
关于办理个人股对价偿还及限售股上市事宜的补充公告
Regulatory Filings Classification · 95% confidence The document is a supplementary announcement regarding the handling of personal stock price repayment and listing of restricted shares by Wuhan Mayinglong Pharmaceutical Group Co., Ltd. It provides procedural details and deadlines for shareholders to cancel designated transactions to facilitate stock transfer and listing. The document is short (911 characters) and primarily serves as an announcement of procedural updates related to share transfer and listing, not a financial report or detailed filing. It does not contain financial statements, audit information, or management discussion. It is not a report publication announcement since it does not mention a report being attached or published. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about share transfer procedures and related shareholder instructions.
2007-07-16 Chinese
第六届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Wuhan Mayinglong Pharmaceutical Group Co., Ltd. It mentions the approval of a 'Corporate Governance Special Activity Self-Inspection Report and Rectification Plan' and refers readers to the Shanghai Stock Exchange website for details. The document is short (353 characters) and does not contain the actual report or detailed financial data. It is an announcement of a board meeting decision related to governance but does not provide the governance report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not neatly fit into other categories.
2007-07-10 Chinese
公司治理专项活动自查报告和整改计划
Governance Information Classification · 95% confidence The document is a detailed report on corporate governance self-inspection and rectification plans of Wuhan Mayinglong Pharmaceutical Group Co., Ltd. It discusses governance structure, shareholder information, internal controls, investor relations, and improvement measures. The content is comprehensive, covering governance practices, board and committee roles, internal control systems, and shareholder relations, consistent with a governance report. It is not a financial report like an annual or interim report, nor is it a brief announcement or a transcript. The document aligns with the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The length and detail confirm it is a full report, not just an announcement or summary.
2007-07-10 Chinese
第六届董事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of Wuhan Mayinglong Pharmaceutical Group Co., Ltd. It includes decisions on organizational restructuring, governance self-assessment and improvement plans, approval of management rules such as the 'Fundraising Management Measures' and 'External Guarantee Management Measures', and implementation of an employee stock ownership plan at subsidiaries. The content focuses on governance, internal controls, and management policies rather than financial results or audit opinions. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a simple announcement of voting results or a proxy statement. The document is a formal disclosure of board/management decisions and governance-related activities. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (4533 characters) and detailed content support this classification with high confidence.
2007-07-10 Chinese
对外担保管理办法
Governance Information Classification · 95% confidence The document is titled '武汉马应龙药业集团股份有限公司 对外担保管理办法' which translates to 'Wuhan Mayinglong Pharmaceutical Group Co., Ltd. External Guarantee Management Measures.' It is a detailed internal management policy document outlining procedures, responsibilities, and rules regarding the company's external guarantees. It includes sections on general principles, guarantee conditions, approval procedures, contract review, risk management, information disclosure, and responsibilities. There is no indication that this is a financial report, audit report, earnings release, or any form of shareholder meeting material. It is not a regulatory filing or announcement but an internal governance document related to company policies and procedures. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 4860 characters, which is sufficient for a substantive policy document rather than a brief announcement.
2007-07-10 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.